Millions of Americans who take an aspirin every day to lower their risk for heart attack and stroke may also be lowering their cancer risk.
New research adds to the growing evidence that daily aspirin may help prevent certain cancers from occurring. On top of that, daily aspirin may also be an effective treatment for people who already have cancer.
In a series of studies published in The Lancet, researchers in the United Kingdom expanded on previous research linking daily low-dose or full-strength aspirin use to a reduced risk of death from cancer over a decade of follow-up.
In their latest work, the researchers examined the short-term impact of aspirin therapy on cancer, finding a reduction in cancers after about three years of daily aspirin use, says University of Oxford professor of medical neurology Peter M. Rothwell, MD, PhD, who led the studies.
People taking aspirin for as few as five years had a lower risk of dying from cancer and of having their disease spread once it had been diagnosed.
Daily Aspirin Reduced Cancer Deaths
In one of the new studies, Rothwell and colleagues analyzed data from 51 trials originally designed to examine the impact of daily aspirin on heart attack and stroke risk.
According to the analysis, taking a low-dose aspirin every day reduced the risk of death from cancer by 37% after at least five years of use.
Taking a daily aspirin for at least three years reduced cancer incidence by close to 25% in both men and women.
In a second study, the researchers examined the impact of daily aspirin therapy on cancer metastasis, or spread, by analyzing newly published data from five other large trials.
Among the findings:
• Over an average follow-up of six-and-a-half years, daily aspirin use was associated with a 36% reduced risk of cancer with distant spread.
• Colorectal cancer patients with localized disease had a 74% reduced risk for having their disease spread when they took a daily aspirin.
• Daily aspirin use was associated with a 35% reduction in cancer deaths among patients with solid tumors, but not blood cancers such as leukemia.